2024/04/15 by Ayesha Abdul Qadir Memon, Areeba Shamim, Sanoober Mirza +3 · 1 voice
Medicine · #Cardiomyopathy and Myosin Studies #Trypanosoma species research and implications #Viral Infections and Immunology Research
paper · pdf · doi:10.2174/0118715257283752240325082733
openalex publication_date 2024/04/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (Camzyos<sup>TM</sup>) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy. This review provides an overview of HCM, its pathophysiology, current treatments, synthesis of Mavacamten, and the clinical trials of Mavacamten.